Vimarsana
Biggest News Aggregation in the World

Page 16 - System Atrophy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from System Atrophy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In System Atrophy Today - Breaking & Trending Today

Appendix 4C - Q4 FY21 Quarterly Cash Flow Report - Vimarsana News

Appendix 4C - Q4 FY21 Quarterly Cash Flow Report

Publication in Presents to MST Access Australian Micro & Small Caps Conference Cash balance at 30 June 2021 of A$28M MELBOURNE, Australia, July 30, 2021 /PRNewswire/ — Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, releases its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 30 June 2021 (Q4 FY21). The Company’s cash position at 30 June 2021 of $28M was bolstered by the receipt of $17M in net...

ATH434 protects brain cells and improves motor function in Parkinsonian disorder - Vimarsana News

ATH434 protects brain cells and improves motor function in Parkinsonian disorder

ATH434 protects brain cells and improves motor function in Parkinsonian disorder Oral presentation at the American Academy of Neurology News provided by Share this article MELBOURNE, Australia  , April 21, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH,NASDAQ: ATHE) ("Alterity" or "the Company") today announced an oral presentation of expanded animal data to support the commercialisation of its lead compound ATH434 in clinical development for the treatment of Parkinsonian disorders, at the American Academy of Neurology (AAN) virtual annual meeting. The AAN conference, held this week, i...

Alterity Therapeutics announces funding from Michael J. Fox Foundation for ATH434 dose optimization for Parkinson's disease clinical trials - Vimarsana News

Alterity Therapeutics announces funding from Michael J. Fox Foundation for ATH434 dose optimization for Parkinson's disease clinical trials

Share this article Share this article NEW YORK, Feb. 9, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH,NASDAQ: ATHE) ("Alterity" or "the Company") has today announced the award of a grant from The Michael J. Fox Foundation for Parkinson's Research to determine optimal dosing of its lead drug candidate ATH434 for Parkinson's disease (PD) based on imaging of brain iron. The funding for US$495,000 will be used to evaluate the pharmacologic profile of ATH434 in a primate model to determine the optimal dose of ATH434 in future Parkinson's disease clinical trials.  This is the second grant t...

2021 Multiple System Atrophy Market to 2030 - Insight, Epidemiology and Forecasts - Vimarsana News

2021 Multiple System Atrophy Market to 2030 - Insight, Epidemiology and Forecasts

Press release content from Business Wire. The AP news staff was not involved in its creation.

Source: apnews.com
Loved ones pay beautiful tributes to 40 Plymouth people who have died - Vimarsana News

Loved ones pay beautiful tributes to 40 Plymouth people who have died

Loved ones pay beautiful tributes to 40 Plymouth people who have died Touching tributes have been paid to 40 people who have passed away recently Updated The video will auto-play soon8Cancel Play now Loved ones have paid beautiful tributes to 40 people from Plymouth who have passed away recently. In total, between January 22 and January 28, 62 death notices were placed, with some people having multiple postings so different family members can pay their respects. There were also ten other messages to remember loved ones who are no longer with us. The notices, placed into the funeral notices se...